TB-161-Dotatate and Lu-177-Dotatate as a tandem therapy

#4290

Introduction: Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell-membrane specific peptide receptors, such as somatostatin receptors.

Aim(s): The aim of this study was to compare the bio-distribution and tumour targeting of Tb-161-Dotatate to Lu-177-Dotatate therapy.

Materials and methods: An 86-year-old female diagnosed with metastatic NET pancreas 2017. The Ki-67 index ranges between 10-67%; Grade 2-3. In 2017/8, the patient received 5 cycles of chemotherapy. In 2018 she had tumour recurrence in the primary bed and received radiotherapy. She was commenced on monthly Sandostatin injections in 2019. She received radiofrequency ablation to the liver metastases in 2020 and 2022. F-18 FDG PET/CT scans from 2020-2022 did not show significant disease outside the liver. In 2022, Ga68 Dotatate PET/CT scan show multiple intense SSR2 positive lesions. Patient received 6 cycles of Lu-177-Dotatate in 2022-2023 with a favourable partial response. A Ga68 Dotatate PET/CT scan showed progression of Dotatate avid pathology in bone. EBRT to T9-T10 was performed. The patient was sent for re-initiation treatment for Lu-Dotatate. Tb-161-Dotatate was used in tandem with Lu-177-Dotatate. Tb-161-Dotatate showed excellent tumour uptake and biodistribution as Lu-177-Dotatate.

Conference:

Presenting Author:

Authors: Hambapersad T, Maharaj M,

Keywords: TB-161-Dotatate, Lu-177-Dotatate, Tandem,